PharmacyCodes



Clorfenesina [INN-Spanish] en es it fr

Clorfenesina [INN-Spanish] Brand names, Clorfenesina [INN-Spanish] Analogs

Clorfenesina [INN-Spanish] Brand Names Mixture

  • No information avaliable

Clorfenesina [INN-Spanish] Chemical_Formula

C52H98N16O13

Clorfenesina [INN-Spanish] RX_link

No information avaliable

Clorfenesina [INN-Spanish] fda sheet

Clorfenesina [INN-Spanish] msds (material safety sheet)

Clorfenesina_[INN-Spanish] MSDS

Clorfenesina [INN-Spanish] Synthesis Reference

No information avaliable

Clorfenesina [INN-Spanish] Molecular Weight

2797.3193 g/mol

Clorfenesina [INN-Spanish] Melting Point

200 - 220 oC

Clorfenesina [INN-Spanish] H2O Solubility

5.64E+005 mg/L

Clorfenesina [INN-Spanish] State

Solid

Clorfenesina [INN-Spanish] LogP

-4.648

Clorfenesina [INN-Spanish] Dosage Forms

Capsule; Cream; Liquid; Ointment; Powder for solution; Solution; Suspension; Tablet; Tablet (enteric-coated); Tablet (extended-release)

Clorfenesina [INN-Spanish] Indication

For the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli, particularly Pseudomonas aeruginosa.

Clorfenesina [INN-Spanish] Pharmacology

Colistin is a polymyxin antibiotic agent. Polymyxins are cationic polypeptides that disrupt the bacterial cell membrane through a detergentlike mechanism. With the development of less toxic agents, such as extended-spectrum penicillins and cephalosporins, parenteral polymyxin use was largely abandoned, except for the treatment of multidrug-resistant pulmonary infections in patients with cystic fibrosis. More recently, however, the emergence of multidrug-resistant gram-negative bacteria, such as Pseudomonas aeruginosa and Acinetobacter baumannii, and the lack of new antimicrobial agents have led to the revived use of the polymyxins.

Clorfenesina [INN-Spanish] Absorption

Very poor absorption from gastrointestinal tract.

Clorfenesina [INN-Spanish] side effects and Toxicity

Oral LD50 in rats is 5450 mg/kg. Overdosage with colistimethate can cause neuromuscular blockade characterized by paresthesia, lethargy, confusion, dizziness, ataxia, nystagmus, disorders of speech and apnea. Respiratory muscle paralysis may lead to apnea, respiratory arrest and death.

Clorfenesina [INN-Spanish] Patient Information

No information avaliable

Clorfenesina [INN-Spanish] Organisms Affected

Gram-negative bacilli